Literature DB >> 28176203

Lipid profiles of donors and recipients of liver transplant: like father like son.

Kevin K W Chu1, See Ching Chan2, Sui Ling Sin1, Albert C Y Chan3, Kenneth S H Chok3, Ignatius K P Cheng4, Chung Mau Lo3.   

Abstract

BACKGROUND/
PURPOSE: Dyslipidemia is common in liver transplant recipients. This retrospective study investigates whether donors play a role.
METHODS: Prospectively collected data of donors and recipients of deceased-donor liver transplantation (DDLT) and living-donor liver transplantation (LDLT) were reviewed. Total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein (HDL) and fasting glucose were compared between groups. HDL ≥1.6 mmol/L at 2 years after transplant was considered the marker of a favorable post-transplant lipid profile in recipients. Univariate and multivariate analyses were performed to identify predictive factors for this marker.
RESULTS: There were 85 DDLTs and 80 LDLTs. LDLT donors were younger (30 vs. 50 years, p < 0.001) and lighter (58.2 vs. 63.4 kg, p = 0.008) and had a lower body mass index (21.2 vs. 23.7, p < 0.001). The DDLT group had more fatty grafts (p = 0.001) and longer cold (375 vs. 103.5 min, p < 0.001) and warm (50.5 vs. 46 min, p = 0.034) ischemia. LDLT donors had lower fasting glucose (4.85 vs. 7.21 mmol/L, p < 0.001) and triglyceride (0.87 vs. 1.22 mmol/L, p = 0.016) but higher HDL (1.58 vs. 1.39 mmol/L, p = 0.022). LDLT recipients also had higher HDL at 1 year (1.48 vs. 1.28 mmol/L, p = 0.026) and 2 years (1.43 vs. 1.21 mmol/L, p = 0.008). Fourteen (16.5%) DDLT recipients and 27 (33.8%) LDLT recipients had HDL ≥1.6 mmol/L at 2 years. On multivariate analysis, donor HDL ≥1.6 mmol/L (RR 4.311, 95% CI 1.666-11.158, p = 0.003) and recipient body mass index <24 (RR 2.753, 95% CI 1.064-7.127, p = 0.037) were the two independent predictive factors.
CONCLUSION: LDLT recipients had better lipid profiles than DDLT recipients. The feature of high HDL level in donors was transferred to recipients.

Entities:  

Keywords:  Cholesterol; Dyslipidemia; Fasting glucose; Lipoprotein; Liver transplant; Triglyceride

Mesh:

Substances:

Year:  2017        PMID: 28176203     DOI: 10.1007/s12072-017-9786-1

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  12 in total

Review 1.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

2.  Hyperlipidemia in liver transplant recipients: prevalence and risk factors.

Authors:  C Gisbert; M Prieto; M Berenguer; M Bretó; D Carrasco; M de Juan; J Mir; J Berenguer
Journal:  Liver Transpl Surg       Date:  1997-07

Review 3.  Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.

Authors:  M M Page; E I Ekinci; R M Jones; P W Angus; P J Gow; R C O'Brien
Journal:  Intern Med J       Date:  2014-06       Impact factor: 2.048

Review 4.  Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity.

Authors:  A Reuben
Journal:  Liver Transpl       Date:  2001-11       Impact factor: 5.799

5.  Risk factors of metabolic disorders after liver transplantation: an analysis of data from fasted patients.

Authors:  Sabine Gebhardt; Maximilian Jara; Maciej Malinowski; Daniel Seehofer; Gero Puhl; Johann Pratschke; Martin Stockmann
Journal:  Transplantation       Date:  2015-06       Impact factor: 4.939

Review 6.  Posttransplant metabolic syndrome: an epidemic waiting to happen.

Authors:  Mangesh Pagadala; Srinivasan Dasarathy; Bijan Eghtesad; Arthur J McCullough
Journal:  Liver Transpl       Date:  2009-12       Impact factor: 5.799

7.  Heart-liver transplantation in a patient with familial hypercholesterolaemia.

Authors:  T E Starzl; D W Bilheimer; H T Bahnson; B W Shaw; R L Hardesty; B P Griffith; S Iwatsuki; B J Zitelli; J C Gartner; J J Malatack
Journal:  Lancet       Date:  1984-06-23       Impact factor: 79.321

8.  Is there disparity between risk and incidence of cardiovascular disease after liver transplant?

Authors:  David A J Neal; Brian D M Tom; Jian'an Luan; Nick J Wareham; Alexander E S Gimson; Luc D Delriviere; Christopher D Byrne; Graeme J M Alexander
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

9.  Prevalence and factors associated with dyslipidemia after liver transplantation.

Authors:  Hélem de Sena Ribeiro; Lucilene Rezende Anastácio; Lívia Garcia Ferreira; Erika Barbosa Lagares; Agnaldo Soares Lima; Maria Isabel Toulson Davisson Correia
Journal:  Rev Assoc Med Bras (1992)       Date:  2014-07       Impact factor: 1.209

10.  Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression.

Authors:  Giampaolo Bianchi; Giulio Marchesini; Rebecca Marzocchi; Antonio D Pinna; Marco Zoli
Journal:  Liver Transpl       Date:  2008-11       Impact factor: 5.799

View more
  1 in total

1.  Predicting dyslipidemia after liver transplantation: A significant role of recipient metabolic inflammation profile.

Authors:  Hai-Tao Huang; Xue-You Zhang; Cheng Zhang; Qi Ling; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.